Abstract:Abstract Cancer immunotherapy has achieved notable clinical success, yet its broader application is impeded primarily by immune evasion mechanisms, predominantly stemming from factors such as tumor antigen loss, intrinsic low antigen presentation, and the inherent impermeability of current macromolecules, including cells, antibodies, and proteins. Consequently, there exists a pressing demand for more permeable agents that target intracellular components as viable alternatives. Among the various molecular players involved in immune evasion, PTPN1 and PTPN2, two protein tyrosine phosphatases (PTPs), play a non-redundant role in regulating tumor antigen presentation. They achieve this by modulating the JAK/STAT signaling pathway within tumor cells, with their deletion having been demonstrated to enhance MHC-I presentation across various cell types. Furthermore, PTPN1 and PTPN2 also negatively regulate T cell receptor (TCR) signaling in T cells, as supported by genetic studies. Consequently, these two proteins present as promising targets for the development of innovative cancer immunotherapies due to their dual impact on both tumor cells and T cells. Addressing the intrinsic impermeability challenges associated with macromolecules, we embarked on the development of small molecule agents that specifically target PTPN1 and PTPN2, culminating in the successful creation of a low-nanomolar proteolysis targeting chimera (PROTAC), designated as X1. PROTAC X1 exhibits sustained low-nanomolar binding affinity and exceptional selectivity toward PTPN1 and PTPN2 in in vitro settings. Furthermore, it has demonstrated a nano-molar half-maximal degradation concentration (DC50) in Jurkat T cells and numerous cancer cell lines, while concurrently exhibiting efficacy in eliciting TCR signaling and enhancing MHC-I presentation. Additionally, X1-treated CAR-T cells exhibited augmented cytotoxicity through increased IFN-γ secretion, thereby reinforcing its efficacy in T cell activation. To ascertain the anti-tumor efficacy of X1, we administered X1 to C57BL/6 mice bearing MC38 tumors, resulting in a significant retardation of tumor progression. Subsequent investigations revealed that X1 treatment induced an inflammatory response in the tumor microenvironment, characterized by enhanced T cell infiltration and the activation of CD8+ T cells. Notably, no discernible adverse effects, such as autoimmune symptoms, were observed during treatment. Collectively, these findings indicate that X1 represents a potent and safe agent for cancer immunotherapy. This study not only elucidates the mechanism of action of PTPN1B/TC-PTP pharmacological degradation as a viable approach for cancer treatment but also solidifies the potential of PTPN1B/TC-PTP degradation as a novel avenue for cancer immunotherapy. Citation Format: Zihan Qu, Yunpeng Bai, Jiajun Dong, Zheng Zhang, Bo Huang, Yiming Miao, Andy W. Tao, Philip S. Low, Zhong-Yin Zhang. Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4505.

Antitumor Effect of F-Pbf Beta-Trcp-Induced Targeted Pttg1 Degradation in Hela Cells

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Antitumor Effect of FP3 on a Patient-Derived Tumor Tissue Xenograft Model of Rectal Carcinoma.

Hpebp4 Resists TRAIL-induced Apoptosis of Human Prostate Cancer Cells by Activating Akt and Deactivating ERK1/2 Pathways*

The Antitumor Agent PBT-1 Directly Targets HSP90 and Hnrnp A2/B1 and Inhibits Lung Adenocarcinoma Growth and Metastasis

Antitumor Effect of FP3 in Combination with Cetuximab on Patient-Derived Tumor Tissue Xenograft Models of Primary Colon Carcinoma and Related Lymphatic and Hepatic Metastases

The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop

Pituitary Tumor Transforming Gene is a Novel Anti-apoptotic Gene in UV-induced Apoptosis

Significance of Pituitary Tumor Transforming Gene 1 (PTTG1) in Prostate Cancer.

PTTG1IP (PBF) is a Prognostic Marker and Correlates with Immune Infiltrate in Ovarian Cancer.

Phosphorylated PTTG1 switches its subcellular distribution and promotes β-catenin stabilization and subsequent transcription activity

An Overview of the Pituitary Tumor-Transforming Gene-1

PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells.

The Important Anti-Apoptotic Role and Its Regulation Mechanism of PTTG1 in UV-induced Apoptosis.

Knockdown of PTTG1 Inhibits the Growth and Invasion of Lung Adenocarcinoma Cells Through Regulation of TGFB1/SMAD3 Signaling.

PUMA: a New Target in Cytoprotective and Tumor Therapy

Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy

BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A

Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer

The expression of pituitary tumor transforming gene (PTTG) in breast cancer and its clinical significance

Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen